Fixed-dose nivolumab plus relatlimab-rmbw (Opdualag) elicited continued progression-free survival (PFS) benefit vs nivolumab (Opdivo) alone in patients with treatment-naïve, unresectable or metastatic melanoma, according to updated results from the phase 2/3 RELATIVITY-047 trial (NCT03470922) that were presented at the 2022 ASCO Annual Meeting.
Posted in Melanoma News, Health Professionals, Of Interest
Analysis included a 29% objective response rate in cohort 4 of the C-144-01 study, the company says.
Posted in Melanoma News, Health Professionals, Clinical Trials
Examine, a weekly newsletter covering the latest developments in science, is sent every Tuesday. Below is an excerpt – sign up to get the whole newsletter in your inbox.
Posted in Melanoma News, Patients, Latest News
TUESDAY, June 7, 2022 (HealthDay News) — U.S. veterans are at higher risk for melanoma, the deadliest form of skin cancer, than most Americans, and new research finds they are also more likely to have advanced-stage disease when it’s detected.
Posted in Melanoma News, Patients, Latest News
 |
 |
 |
 |
